eFFECTOR Therapeutics to Participate in 2021 Cantor Virtual Healthcare Conference
September 16, 2021 08:00 ET
|
eFFECTOR Therapeutics, Inc.
SAN DIEGO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer,...
eFFECTOR Therapeutics Debuts as Publicly Traded Next-Generation Oncology Company Advancing Mature Pipeline with New Class of Cancer Therapies
August 25, 2021 19:18 ET
|
eFFECTOR Therapeutics, Inc.
SAN DIEGO, Aug. 25, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (eFFECTOR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer,...
eFFECTOR Therapeutics Initiates Phase 2a Expansion Cohorts Evaluating Zotatifin in Breast Cancer and KRAS-mutant Non-small Cell Lung Cancer
August 04, 2021 08:00 ET
|
eFFECTOR Therapeutics
SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (eFFECTOR), a leader in the development of selective translation regulation inhibitors (STRIs) for the treatment of cancer,...
eFFECTOR Therapeutics Doses First Patient with COVID-19 in Phase 1b Clinical Trial Evaluating Zotatifin as a Host-Targeted Antiviral Agent
July 22, 2021 08:00 ET
|
eFFECTOR Therapeutics
SAN DIEGO, July 22, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors (STRIs) for the treatment of cancer, today...
eFFECTOR Therapeutics Announces Publication of Tomivosertib Preclinical Data in Cell Reports
July 16, 2021 08:00 ET
|
eFFECTOR Therapeutics
SAN DIEGO, July 16, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors (“STRIs”) for the treatment of cancer, announced...
eFFECTOR Therapeutics to Present at JMP Securities 2021 Life Sciences Conference
June 14, 2021 08:00 ET
|
eFFECTOR Therapeutics
SAN DIEGO, June 14, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (“eFFECTOR”), a biopharmaceutical company focused on pioneering the development of selective translation regulation...
eFFECTOR Therapeutics Doses First Patient in Phase 2b KICKSTART Clinical Trial
June 09, 2021 08:00 ET
|
eFFECTOR Therapeutics
SAN DIEGO, June 09, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors (STRIs) for the treatment of cancer, today...
eFFECTOR Therapeutics and Locust Walk Acquisition Corp. Announce Merger Agreement to Create Publicly Listed, Next-Generation Oncology Company Developing New Class of Cancer Therapies
May 27, 2021 08:00 ET
|
eFFECTOR Therapeutics
Gross proceeds expected to include $60 million from a committed PIPE and up to $175 million held in trust Anticipated cash resources will fund eFFECTOR’s pipeline advancement through multiple clinical...
eFFECTOR and Quantitative Biosciences Institute (QBI) at UCSF Receive $5.0 Million from DARPA to Evaluate Zotatifin in COVID-19
May 04, 2021 08:00 ET
|
eFFECTOR Therapeutics
SAN DIEGO, May 04, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today...
eFFECTOR Appoints Mike Byrnes as Chief Financial Officer
January 07, 2021 08:00 ET
|
eFFECTOR Therapeutics
SAN DIEGO, Jan. 07, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors (STRIs) for the treatment of cancer, today...